128 related articles for article (PubMed ID: 37148468)
1. Neoadjuvant chemotherapy in patients undergoing neoadjuvant radiation for trunk and extremity soft tissue sarcoma.
Tortorello GN; Sharon CE; Ma KL; Perry N; Shabason JE; Maki RG; Miura JT; Karakousis GC
J Surg Oncol; 2023 Sep; 128(4):628-634. PubMed ID: 37148468
[TBL] [Abstract][Full Text] [Related]
2. Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative.
Zaidi MY; Ethun CG; Tran TB; Poultsides G; Grignol VP; Howard JH; Bedi M; Mogal H; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Krasnick B; Fields RC; Oskouei S; Reimer N; Monson D; Maithel SK; Cardona K
Ann Surg Oncol; 2019 Oct; 26(11):3542-3549. PubMed ID: 31342400
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemotherapy in Retroperitoneal Sarcoma: A National Cohort Study.
Tortorello GN; Li EH; Sharon CE; Ma KL; Maki RG; Miura JT; Fraker DL; DeMatteo RP; Karakousis GC
Ann Surg Oncol; 2023 Oct; 30(11):6886-6893. PubMed ID: 37488394
[TBL] [Abstract][Full Text] [Related]
4. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
5. Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study.
Bonvalot S; Wunder J; Gronchi A; Broto JM; Turcotte R; Rastrelli M; Papai Z; Radaelli S; Lindner LH; Shumelinsky F; Cubillo A; Rutkowski P; Demaire C; Strens D; Nalbantov G
Eur J Surg Oncol; 2021 Aug; 47(8):2166-2172. PubMed ID: 33676792
[TBL] [Abstract][Full Text] [Related]
6. The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
Goy BW; Syed S; Padmanabhan A; Burchette RJ; Helmstedter CS
Radiother Oncol; 2021 Dec; 165():174-178. PubMed ID: 34758339
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.
Mullen JT; Hornicek FJ; Harmon DC; Raskin KA; Chen YL; Szymonifka J; Yeap BY; Choy E; DeLaney TF; Nielsen GP
Cancer; 2014 Dec; 120(23):3676-82. PubMed ID: 25081640
[TBL] [Abstract][Full Text] [Related]
8. Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score.
Schaefer IM; Hornick JL; Barysauskas CM; Raut CP; Patel SA; Royce TJ; Fletcher CDM; Baldini EH
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):375-383. PubMed ID: 28463157
[TBL] [Abstract][Full Text] [Related]
9. Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity/trunk soft-tissue sarcoma?
Chowdhary M; Chowdhary A; Sen N; Zaorsky NG; Patel KR; Wang D
Cancer; 2019 Nov; 125(21):3801-3809. PubMed ID: 31490546
[TBL] [Abstract][Full Text] [Related]
10. Assessment of multimodality therapy use for extremity sarcoma in the United States.
Sherman KL; Wayne JD; Chung J; Agulnik M; Attar S; Hayes JP; Laskin WB; Peabody TD; Bentrem DJ; Pollock RE; Bilimoria KY
J Surg Oncol; 2014 Apr; 109(5):395-404. PubMed ID: 24375444
[TBL] [Abstract][Full Text] [Related]
11. Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival in patients with soft-tissue sarcoma.
Rao SR; Lazarides AL; Leckey BL; Lane WO; Visgauss JD; Somarelli JA; Kirsch DG; Larrier NA; Brigman BE; Blazer DG; Cardona DM; Eward WC
Cancer Med; 2022 Jan; 11(1):194-206. PubMed ID: 34837341
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
Gronchi A; Palmerini E; Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Braglia L; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
J Clin Oncol; 2020 Jul; 38(19):2178-2186. PubMed ID: 32421444
[TBL] [Abstract][Full Text] [Related]
13. Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas.
Squires MH; Ethun CG; Suarez-Kelly LP; Yu PY; Hughes TM; Shelby RD; Tran TB; Poultsides G; Charlson J; Gamblin TC; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Krasnick BA; Fields RC; Pollock RE; Grignol V; Cardona K; Howard JH
J Surg Res; 2020 Jan; 245():577-586. PubMed ID: 31494391
[TBL] [Abstract][Full Text] [Related]
14. Follow-up after primary treatment of soft tissue sarcoma of extremities: impact of frequency of follow-up imaging on disease-specific survival.
Chou YS; Liu CY; Chen WM; Chen TH; Chen PC; Wu HT; Chiou HJ; Shiau CY; Wu YC; Liu CL; Chao TC; Tzeng CH; Yen CC
J Surg Oncol; 2012 Aug; 106(2):155-61. PubMed ID: 22297812
[TBL] [Abstract][Full Text] [Related]
15. Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy.
Bedi M; King DM; Shivakoti M; Wang T; Zambrano EV; Charlson J; Hackbarth D; Neilson J; Whitfield R; Wang D
Radiat Oncol; 2013 Mar; 8():60. PubMed ID: 23497372
[TBL] [Abstract][Full Text] [Related]
16. The influence of anatomic location on outcomes in patients with localized primary soft tissue sarcoma.
Zhao R; Yu X; Feng Y; Wang J; Mao Y; Yin W; Zhang Z; Guo X; Ma S
Jpn J Clin Oncol; 2018 Sep; 48(9):799-805. PubMed ID: 30060202
[TBL] [Abstract][Full Text] [Related]
17. The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma.
Kobus M; Roohani S; Ehret F; Flörcken A; Striefler JK; Brandes F; Märdian S; Rau D; Wittenberg S; Öllinger R; Kaul D
Radiat Oncol; 2022 Aug; 17(1):139. PubMed ID: 35941656
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Radiotherapy is Associated with R0 Resection and Improved Survival for Patients with Extremity Soft Tissue Sarcoma Undergoing Surgery: A National Cancer Database Analysis.
Gingrich AA; Bateni SB; Monjazeb AM; Darrow MA; Thorpe SW; Kirane AR; Bold RJ; Canter RJ
Ann Surg Oncol; 2017 Oct; 24(11):3252-3263. PubMed ID: 28741123
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL
BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211
[TBL] [Abstract][Full Text] [Related]
20. Soft tissue sarcoma brain metastases. Prevalence in a cohort of 3829 patients.
Espat NJ; Bilsky M; Lewis JJ; Leung D; Brennan MF
Cancer; 2002 May; 94(10):2706-11. PubMed ID: 12173340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
